Asta Evans is an associate in Goodwin’s Tax practice. Ms. Evans advises on all aspects of UK and international taxation with particular emphasis on fund structuring, reorganisations, initial public offerings, general corporate and capital market matters as well as advising on tax aspects of financing transactions. Prior to joining Goodwin, Ms. Evans was a senior associate at Clifford Chance.
Areas of Practice
Domaines D’Expertise





Ms. Evan’s recent representative experience includes advising:

  • Goldman Sachs & Co. LLC and the other underwriters of Exscientia plc’s upsized initial public offering in the United States of 15,927,500 American Depositary Shares representing 15,927,500 ordinary shares, including 2,077,500 ADSs sold pursuant to the full exercise of the underwriters’ previously granted option to purchase additional ADSs
  • Quanta Dialysis Technologies on its completion of a $245 million oversubscribed Series D funding round, the largest private funding round for a dialysis device company in history
  • Centessa Pharmaceuticals plc, a next-generation biopharmaceutical company that aims to reshape the traditional drug development process, on its $379.5 million initial public offering 
  • Achilles Therapeutics, a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer, on its $175.5 million initial public offering
  • TA Associates and Stirling Square Capital Partners on two significant acquisitions by their joint portfolio company Byggfakta Group
  • TowerBrook Capital Partners L.P., a purpose-driven investment management firm, and its co-founders on the establishment of a new real estate lending platform called Precis Capital Partners
  • The underwriters of $158.8 Million Freeline initial public offering
  • The underwriters of $85.1 Million RenalytixAI global offering
  • Biotech KaNDy Therapeutics and its shareholders in connection with KaNDy’s agreement to be acquired by Bayer
  • Royalty Pharma plc on an offering of US $6 billion in aggregate principal amount of its (i) 0.750% Senior Notes due 2023, (ii) 1.200% Senior Notes due 2025, (iii) 1.750% Senior Notes due 2027, (iv) 2.200% Senior Notes due 2030, (v) 3.300% Senior Notes due 2040 and (vi) 3.550% Senior Notes due 2050, in a private placement pursuant to Rule 144A and Regulation S
  • COMPASS Pathways plc on its upsized US $146.6 million initial public offering
  • Royalty Pharma plc on an underwritten secondary offering of 17,343,037 of its Class A ordinary shares, at a public offering price of US $42.00 per share and for gross proceeds of US $728 million, before deducting underwriting discounts and other offering expenses
  • Antin Infrastructure Partners on the sale of a minority strip of four of the assets (three of which comprise fibre networks businesses) from its existing Fund III to Antin Infrastructure Partners III-B SCSp, a new “Annex Fund”, raising €1.235 billion of further commitments from a consortium
  • Wintermute Trading Limited on its US $20 million Series B funding round
  • Orchard Therapeutics plc on its previously announced PIPE of 24,115,755 of its voting and non-voting ordinary shares for gross proceeds of US $150 million
  • Centessa Pharmaceuticals Limited on the completion of its US $250 million financing round in parallel with the simultaneous acquisition by Centessa of 10 private biotech companies across 4 jurisdictions (UK, USA, Germany and France)

In The News









Legal Practice Course
University of Law
Graduate Diploma in Law
University of Westminster
Bachelor of Jurisprudence
Concordia International University (Estonia)
Saules Gimnazija, Birzai, Lithuania



Solicitor of England and Wales
Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique